Printer Friendly

Competitive Technologies, Inc. Licenses Homocysteine Assay to Genzyme; Genzyme's Equal Diagnostic Homocysteine Assays Carry Pass-Through License to Customers.

FAIRFIELD, Conn. -- Competitive Technologies, Inc. (AMEX: CTT) today announced that a homocysteine assay license has been granted to Genzyme Diagnostics under CTT's U.S. Patent Number 4,940,658 relating to homocysteine medical tests. The license includes an initial license fee and payments, releasing Equal Diagnostics (a Genzyme business) customers of any obligation to pay royalties to CTT for homocysteine test results obtained using Genzyme's Equal Diagnostics assays in the past. The license also includes royalties on future product sales.

"We are very pleased to issue this license to Genzyme, a recognized leader in biotechnology and diagnostics," said Aris D. Despo, CTT's Senior VP Life Sciences. "This agreement marks another successful step in CTT's active licensing and royalty collection program for the homocysteine assay. We are pleased to develop this relationship with Genzyme, which also opens the door for future collaboration."

"This license demonstrates our commitment to our customers and their needs," stated Donald E. Pogorzelski, President of Genzyme Diagnostics, "and, permits Genzyme Equal customers to continue performing homocysteine assays under Genzyme's license with CTT."

Dr. D. J. Freed, CTT's President and CEO, said, "The agreement with Genzyme is further validation of CTT's homocysteine licensing program. CTT continues to expand its recurring revenue stream by building valued relationships with industry leaders."

The homocysteine patent is derived from discoveries made by CTT's clients, Drs. Robert Allen and Sally Stabler from the University of Colorado, and the late Dr. John Lindenbaum from Columbia University. The license does not relieve Genzyme's customers for royalties on past or future assays for methylmalonic acid, for which CTT will separately require a license to perform such assays.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Founded in 1981, Genzyme has grown from a small start-up to a diversified enterprise with annual revenues exceeding $2 billion and more than 8,000 employees in locations spanning the globe. With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life and physical sciences, electronics, and nanotechnologies developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit our website at: www.competitivetech.net.

Statements about our future expectations, including development and regulatory plans, and all other statements in this press release, other than historical facts, are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. If and when used herein, the words "anticipate," "believe," "intend," "plan," "expect," "estimate," "approximate," and similar expressions, as they relate to us or our business or management, are intended to identify such forward-looking statements. These statements involve risks and uncertainties related to market acceptance of and competition for our licensed technologies, growth strategies, operating performance, industry trends, and other risks and uncertainties inherent in our business, including those set forth in Item 7 under the caption "Risk Factors," in our most recent Annual Report on Form 10-K for the year ended July 31, 2005, filed with the Securities and Exchange Commission ("SEC") on October 13, 2005, and other factors that may be described in our other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Company Profile
Geographic Code:1USA
Date:Dec 21, 2005
Words:680
Previous Article:Steve Owings Steps Down From ScanSource Board; Jim Foody to Assume Role as Board Chairman.
Next Article:Friendster Reduces Network Costs; Optimizes Performance with Internap Route Control Technology; FlowControl Platform Provides Control and Visibility...
Topics:


Related Articles
GENZYME MOLECULAR ONCOLOGY & COMPUGEN COLLABORATE IN EXPANSION.
Firms vie to treat genetic disease.
PHASE 3 TRIAL/STUDY OF ALDURAZYME FOR MPS I PROMISING.
Hypercoagulability as a cause of stroke in adults. (Featured CME Topic: Stroke).
Risk-factor profile in severe, generalized, obliterating vascular disease.
Concentrations of B vitamins and homocysteine in children with sickle cell anemia.
Blood lead is a predictor of homocysteine levels in a population-based study of older adults.
GENZYME FILES FOR EUROPEAN APPROVAL OF SYNVISC.
Determinants of plasma homocysteine in relation to hematological and biochemical variables in patients with acute myocardial infarction.
Neural tube defects and folate pathway genes: family-based association tests of gene-gene and gene-environment interactions.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters